A randomized placebo-controlled phase 3 trial of an antisense oligonucleotide, drisapersen, in Duchenne muscular dystrophyNathalie Goemans, Yasuhiro Takeshima, Eugenio Mercuri et al.|Neuromuscular Disorders|2017Cited by 128
HNRNPDL-related muscular dystrophy: expanding the clinical, morphological and MRI phenotypesAndrés Berardo, Ana Lía Taratuto, Xavière Lornage et al.|Journal of Neurology|2019Cited by 55
The Clinical Development of Taldefgrobep Alfa: An Anti-Myostatin Adnectin for the Treatment of Duchenne Muscular DystrophyFrancesco Muntoni, Alberto Dubrovsky, Amita Bansal et al.|Neurology and Therapy|2024Cited by 23